{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99"}]}],"title":"Day 30"},{"categories":[{"measurements":[{"groupId":"OG000","value":"101"}]}],"title":"Day 60"}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"}],"units":"Participants"}],"description":"Number of patients who achieved 100% donor chimerism.","groups":[{"description":"Myeloablative bone marrow transplant with a busulfan (Bu), cyclophosphamide (Cy), preparative regimen and post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis.","id":"OG000","title":"Bone Marrow Transplant"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The study data was analyzed early after 117 participants had been treated. This was done in order to publish the data and establish a new local standard of care at our institution. Chimerism data was not collected on the remaining 25 participants. One participant died prior to Day 30 and was not analyzed for this outcome.","reportingStatus":"POSTED","timeFrame":"Day 30, Day 60","title":"Chimerism","type":"SECONDARY","unitOfMeasure":"Participants"}